Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial

ASIAIR > College of Medical and Health Science > Department of Psychology > Journal Article > Item 310904400/115254

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/115254

Title:	Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial
Authors:	CH, Lin;CH, Lin;SH, Wang;SH, Wang;藍先元;Lane, Hsien Yuan
Contributors:	醫學暨健康學院心理學系
Keywords:	Cognition;N-methyl-D-aspartate;late;life depression;perceive stress;sodium benzoate.
Date:	2022-08-01
Issue Date:	2023-03-29 01:07:14 (UTC+0)
Publisher:	亞洲大學
Abstract:	Background: Compared with adults with depression in the general population, elderly depressive patients are prone to poor treatment response, more side effects, and early withdrawal with current antidepressants (which principally modulate monoamines). Whether N-methyl-D-aspartate receptor enhancement can benefit treatment of late-life depression deserves study. This study aims to compare sodium benzoate (a D-amino acid oxidase inhibitor and an indirect N-methyl-D-aspartate receptor enhancer), sertraline (a selective serotonin reuptake inhibitor), and placebo in the treatment of late-life depression. Methods: In this randomized, double-blind trial, 117 patients with major depressive disorder aged 55 years or older received 8-week treatment of 250-1500 mg/d of sodium benzoate, 25-150 mg/d of sertraline, or placebo in 2 medical centers. The primary outcome measures were Hamilton Depression Rating Scale and Perceived Stress Scale scores. Results: Three treatments similarly decreased clinicians-rated Hamilton Depression Rating Scale scores. Compared with placebo, sodium benzoate but not sertraline substantially improved Perceived Stress Scale scores and cognitive function. Sertraline, but not benzoate, significantly reduced self-report Geriatric Depression Scale scores. Benzoate and placebo showed similar safety profiles, while sertraline was more likely to raise low-density lipoprotein than benzoate and placebo. Benzoate-treated patients were less likely to drop out than sertraline or placebo recipients. Conclusions: Sertraline can reduce subjective depressive symptoms, while benzoate can decrease perceived stress, improve cognitive function, and enhance treatment adherence in late-life depression patients. The results show promise for D-amino acid oxidase inhibition as a novel approach for perceived stress and cognitive decline among patients with late-life depression.
Appears in Collections:	[Department of Psychology] Journal Article

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	82	View/Open

Loading...